Clinical Trials

Phase 1 Active not recruiting

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Phase 1 Recruiting

14 enrolled

Prostatic Neoplasms

NCT06114940 2026-03-05

PLUTO

17 enrolled

Carcinoma, Renal Cell

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

CNSEndocrineGenitourinary

40 enrolled

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT06255223 2025-09-03

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

Phase 2 Recruiting

35 enrolled

Carcinoma, Renal Cell

NCT03815942 2025-06-25

ADVANCE

Phase 1/2 Terminated

23 enrolled 11 charts

Intermediate Risk Prostate Cancer

NCT04152018 2025-05-28

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

GastrointestinalGenitourinaryGynecologicHead & Neck

85 enrolled

Squamous Cell Carcinoma of Head and Neck, Bile Duct Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

184 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03991130 2025-02-06

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

DermatologicGenitourinary

6 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT03549000 2024-12-13

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

BreastGenitourinaryGynecologicThoracic

127 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

315 enrolled 73 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

4 enrolled 9 charts

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Phase 1/2 Terminated

252 enrolled 67 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1 Completed

298 enrolled

BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

BreastGastrointestinalGenitourinaryHead & NeckThoracic

61 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1/2 Completed

490 enrolled 77 charts

DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1 Completed

120 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04385654 2020-05-13

Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma

Phase 2 Unknown

40 enrolled

Kidney Neoplasms, Neoplasm Metastasis

NCT01420965 2019-07-10

Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer

7 enrolled 7 charts